PF-06305591

PF-06305591 is a potent and highly selective small molecule blocker of the voltage-gated sodium channel NaV1.8 (encoded by SCN10A), with an IC50 of approximately 15 nM[2][3][8]. It was developed by Pfizer for the potential treatment of pain conditions, particularly those involving inflammatory and neuropathic pain[5][8]. The compound demonstrates high selectivity for NaV1.8 over other sodium channel subtypes and has shown favorable preclinical ADME properties as well as safety in early clinical studies[3][5][8]. Clinical trials have included Phase 1 studies assessing safety and tolerability in healthy volunteers[4].

Other names

1H-benzimidazole-2-propanamide, beta-amino-6-(1,1-dimethylethyl)-alpha-methyl-, (alpha.R,2S)-DB12106DB-12106DB 12106G5Y3F1X9MU (UNII)1449473-97-5 (CAS number)